Nothing Special   »   [go: up one dir, main page]

ATE270544T1 - Halbfeste arzneizubereitung enthaltend isotretinoin - Google Patents

Halbfeste arzneizubereitung enthaltend isotretinoin

Info

Publication number
ATE270544T1
ATE270544T1 AT01969090T AT01969090T ATE270544T1 AT E270544 T1 ATE270544 T1 AT E270544T1 AT 01969090 T AT01969090 T AT 01969090T AT 01969090 T AT01969090 T AT 01969090T AT E270544 T1 ATE270544 T1 AT E270544T1
Authority
AT
Austria
Prior art keywords
semi
preparation containing
medicinal preparation
solid medicinal
isotretinoin
Prior art date
Application number
AT01969090T
Other languages
English (en)
Inventor
Francis Vanderbist
Cecile Servais
Philippe Baudier
Original Assignee
Galephar M F
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3862550&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE270544(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Galephar M F filed Critical Galephar M F
Application granted granted Critical
Publication of ATE270544T1 publication Critical patent/ATE270544T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203Retinoic acids ; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT01969090T 2000-09-22 2001-09-21 Halbfeste arzneizubereitung enthaltend isotretinoin ATE270544T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BE0000111 2000-09-22
PCT/BE2001/000163 WO2002024172A1 (en) 2000-09-22 2001-09-21 Pharmaceutical semi-solid composition of isotretinoin

Publications (1)

Publication Number Publication Date
ATE270544T1 true ATE270544T1 (de) 2004-07-15

Family

ID=3862550

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01969090T ATE270544T1 (de) 2000-09-22 2001-09-21 Halbfeste arzneizubereitung enthaltend isotretinoin

Country Status (10)

Country Link
US (5) US7435427B2 (de)
EP (1) EP1318791B1 (de)
AT (1) ATE270544T1 (de)
AU (1) AU2001289438A1 (de)
BR (1) BR102013032172A2 (de)
CA (1) CA2423170A1 (de)
DE (1) DE60104206T2 (de)
ES (1) ES2225600T3 (de)
PT (1) PT1318791E (de)
WO (1) WO2002024172A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU782966B2 (en) 1999-06-08 2005-09-15 University Of Iowa Research Foundation, The Compounds and methods to enhance RAAV transduction
US7435427B2 (en) 2000-09-22 2008-10-14 Galephar M/F Pharmaceutical semi-solid composition of isotretinoin
ITMI20011338A1 (it) * 2001-06-26 2002-12-26 Farmatron Ltd Composizioni farmaceutiche orali a rilascio immediato del principio attivo
FI20030426A (fi) * 2003-03-24 2004-09-25 Tomi Jaervinen Syklodekstriinikompleksit
EP1608410A2 (de) 2003-03-31 2005-12-28 University of Iowa Research Foundation Pharmazeutische therapie und gentherapie von krankheiten, die mit dem epithelialen natriumkanal assoziert sind
SE0303135D0 (sv) * 2003-11-25 2003-11-25 Lipocore Holding Ab Controlled food effect composition
MX2007011250A (es) * 2005-03-21 2007-11-14 Ivax Pharmaceuticals Sro Inhibidor de la cristalizacion y su uso en capsulas de gelatina.
CA2677842C (en) 2007-02-16 2014-09-16 Aska Pharmaceutical Co., Ltd. Pharmaceutical composition comprising microparticle oily suspension
WO2010109259A1 (es) * 2009-03-26 2010-09-30 Grufarcol Ltda Métoda para preparar formulaciones de gel blando de isotretinoína líquida y la formulaciones obtenidas
CA2762394C (en) 2009-05-20 2016-07-19 Ranbaxy Laboratories Limited Topical retinoid solutions
CN102802729A (zh) 2009-05-20 2012-11-28 兰贝克赛实验室有限公司 异维a酸的液体剂型
US10022348B2 (en) 2009-05-20 2018-07-17 Sun Pharmaceutical Industries Limited Topical solution of isotretinoin
US9078925B2 (en) * 2012-06-18 2015-07-14 Galephar Pharmaceutical Research, Inc. Pharmaceutical semi-solid composition of isotretinoin
WO2015047769A1 (en) 2013-09-25 2015-04-02 3M Innovative Properties Company Compositions for electric field grading
EP3094635B1 (de) 2014-01-17 2018-07-04 Oncoral Pharma ApS Oral anzuwendende feste darreichungsform von irinotecan zur behandlung von krebs
MX2016015465A (es) 2014-05-29 2017-03-27 Sun Pharmaceutical Ind Ltd Composicion farmaceutica oral de isotretinoina.
WO2015186039A1 (en) * 2014-06-02 2015-12-10 Sun Pharmaceutical Industries Limited Oral pharmaceutical composition of isotretinoin
JP2017521470A (ja) 2014-07-31 2017-08-03 サン ファーマシューティカル インダストリーズ リミテッドSun Pharmaceutical Industries Ltd. イソトレチノインの経口医薬組成物
US9750711B2 (en) 2014-10-01 2017-09-05 Sun Pharmaceutical Industries Limited Low dose oral pharmaceutical composition of isotretinoin
MA40781A (fr) * 2014-10-01 2017-08-08 Sun Pharmaceutical Ind Ltd Composition pharmaceutique d'isotrétinoïne à faible dosage destinée à la voie orale
CA2987177A1 (en) * 2015-05-25 2016-12-01 Sun Pharmaceutical Industries Limited Once-daily oral pharmaceutical composition of isotretinoin
AU2015397336A1 (en) * 2015-05-29 2017-12-21 Sun Pharmaceutical Industries Limited Oral pharmaceutical composition of isotretinoin
US11702672B2 (en) 2016-02-08 2023-07-18 University Of Iowa Research Foundation Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
US11684679B2 (en) 2016-03-07 2023-06-27 University Of Iowa Research Foundation AAV-mediated expression using a synthetic promoter and enhancer
CA3062764A1 (en) 2016-04-28 2017-11-02 Amplipharm Pharmaceuticals, LLC Temozolomide powder formulation
US9949967B2 (en) 2016-04-28 2018-04-24 Amplipharm Pharmaceuticals, LLC Temozolomide powder formulation
US10285987B2 (en) 2017-04-28 2019-05-14 Amplipharm Pharmaceuticals, LLC Device and kit for dosing and dispensing non-liquid medicine
WO2017203365A1 (en) 2016-05-26 2017-11-30 Dr. Reddy's Laboratiories Ltd. Pharmaceutical compositions for treating acne
WO2018132747A1 (en) 2017-01-13 2018-07-19 University Of Iowa Research Foundation Bocaparvovirus small noncoding rna and uses thereof
CA3061125C (en) * 2017-04-28 2022-05-24 Amplipharm Pharmaceuticals, LLC Device and kit for dosing and dispensing non-liquid medicine
EA202090164A1 (ru) 2017-06-29 2020-05-14 СКАЙЛАЙН БАЙОСАЙЕНСИЗ, ЭлЭлСи Изотретиноиновые перорально-слизистые композиции и способы их применения
US10716774B1 (en) 2018-01-05 2020-07-21 Yale Pharmaceuticals LLC Pharmaceutical compositions containing isotretinoin with improved dissolution profile and enhanced stability
EP4236915A4 (de) * 2020-11-01 2024-10-23 Idrs Labs Pvt Ltd Orale flüssige pharmazeutische zusammensetzungen von isotretinoin
WO2024006748A1 (en) 2022-07-01 2024-01-04 Acrotech Biopharma Inc. Pharmaceutical compositions comprising isotretinoin and processes for preparation and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA713539B (en) 1970-06-23 1972-02-23 Hoffmann La Roche Pharmaceutical compositions
US4530213A (en) 1983-06-28 1985-07-23 Air Products And Chemicals, Inc. Economical and thermally efficient cryopump panel and panel array
US4678663A (en) * 1984-02-06 1987-07-07 Nuetrogena Corporation Hydroquinone composition having enhanced bio-availability and percutaneous adsorption
CA1282326C (en) * 1984-12-14 1991-04-02 Paul J. Jarosz Pharmaceutical composition containing 13-cis vitamin a acid as the active ingredient
US5252604A (en) * 1992-07-10 1993-10-12 Hoffmann-La Roche Inc. Compositions of retinoic acids and tocopherol for prevention of dermatitis
US6054136A (en) 1993-09-30 2000-04-25 Gattefosse S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
US5993858A (en) * 1996-06-14 1999-11-30 Port Systems L.L.C. Method and formulation for increasing the bioavailability of poorly water-soluble drugs
US5993585A (en) * 1998-01-09 1999-11-30 Nike, Inc. Resilient bladder for use in footwear and method of making the bladder
US6020003A (en) * 1998-02-23 2000-02-01 Basf Corporation Method of making spray-dried powders with high edible-oil loadings based on non-hydrolyzed gelatin
FR2775597B1 (fr) 1998-03-04 2001-04-20 Gattefosse Ets Sa Pellet administrable par voie orale apte a ameliorer la biodisponibilite de la substance active, procede de fabrication
KR100336090B1 (ko) * 1998-06-27 2002-05-27 윤승원 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제
PE20001227A1 (es) 1998-10-30 2000-11-06 Hoffmann La Roche Procesos para producir una composicion de isotretinoina
WO2000025572A1 (en) 1998-11-04 2000-05-11 Jagjit Singh Kaurah Improved automatic plant watering system and water level control
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6624154B1 (en) * 1999-04-23 2003-09-23 Bristol-Myers Squibb Company Compositions and methods for treatment of hyperproliferative diseases
AU769315B2 (en) * 1999-08-24 2004-01-22 Cellgate, Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
US6267798B1 (en) * 2000-02-02 2001-07-31 Nuflux, Llc Composition for treating steel making slags
IN192188B (de) * 2000-06-16 2004-03-13 Ranbaxy Lab Ltd
US7435427B2 (en) 2000-09-22 2008-10-14 Galephar M/F Pharmaceutical semi-solid composition of isotretinoin
CN102802729A (zh) 2009-05-20 2012-11-28 兰贝克赛实验室有限公司 异维a酸的液体剂型
RU2400226C1 (ru) 2009-06-08 2010-09-27 Юрий Степанович Макляков Способ лечения угревой болезни

Also Published As

Publication number Publication date
US8367102B2 (en) 2013-02-05
US8952064B2 (en) 2015-02-10
CA2423170A1 (en) 2002-03-28
AU2001289438A1 (en) 2002-04-02
EP1318791A1 (de) 2003-06-18
US20040009225A1 (en) 2004-01-15
BR102013032172A2 (pt) 2017-10-24
US20080171084A1 (en) 2008-07-17
ES2225600T3 (es) 2005-03-16
DE60104206D1 (de) 2004-08-12
US20130217769A1 (en) 2013-08-22
US7435427B2 (en) 2008-10-14
US20130096196A1 (en) 2013-04-18
DE60104206T2 (de) 2005-09-22
US9089534B2 (en) 2015-07-28
US20130158119A1 (en) 2013-06-20
WO2002024172A1 (en) 2002-03-28
PT1318791E (pt) 2004-11-30
EP1318791B1 (de) 2004-07-07

Similar Documents

Publication Publication Date Title
ATE270544T1 (de) Halbfeste arzneizubereitung enthaltend isotretinoin
ATE293995T1 (de) Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten
BR0111016A (pt) Composições farmacêuticas de liberação sustentada para a administração parenteral de compostos hidrófilos biologicamente ativos
ATE554750T1 (de) Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungen
AR021844A1 (es) Derivados de propanolamina aril-sustituidos, procedimientos para su preparacion, medicamentos que contienen estos compuestos y su utilizacion
BR9810495A (pt) Composição farmacêutica
SE0001899D0 (sv) New compounds
BR0015188A (pt) Composições farmacêuticas
EE200300033A (et) Tsüklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
DE69940769D1 (de) Orale flüssige zusammensetzungen
BR9611802A (pt) Composições farmacêuticas
BR9907647A (pt) Composições contendo composto orgânicos
BR0214679A (pt) Composições farmacêuticas compreendendo compostos a base de vitamina d ativa
HUP9901144A2 (hu) Hatóanyagként klopidogrel és egy antitrombotikum új kombinációját tartalmazó gyógyszerkészítmények
ATE302616T1 (de) Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe
CY1110258T1 (el) Υποκατεστημενα παραγωγα c-κυκλοεξυλομεθυλαμινης
ATE530197T1 (de) Medizinische zusammensetzungen zur angiogenese- therapie
TR199801861T2 (xx) Farmas�tik olarak yararl� bile�imler.
ATE406161T1 (de) Kombination aus tenofovir, ritonavir und tmc114
RS50768B (sr) Režim doziranja i farmaceutska formulacija za urgentnu zaštitu
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
PT1121127E (pt) Composicoes farmaceuticas orais contendo buprenorfina
DE60202590D1 (de) 2h-1-benzopyran-derivate, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
ATE342734T1 (de) Adenosin a1 antagonisten gegen männliche sterilität
BR0206960A (pt) Composição farmacêutica oral, e, uso de um polìmero de ftalato de hidroxipropilmetilcelulose

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties